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Background: Fluorescence-based cell-free assays offer an attractive alternative to current cell-based assays for
measuring the redox activity of High-Density Lipoprotein (HDL). We have recently developed a biochemical assay
that assesses the effect of HDL on the oxidation rate of dihydrorhodamine 123 (DHR), reflected by increasing
fluorescence over time. However, an immediate reduction in the fluorescence signal is observed after addition of
HDL to DHR, due to fluorescence quenching from lipid-probe interactions. Understanding this process is important
for interpretation of the results of all fluorescence-based cell-free assays that measure oxidative properties of lipids.
Methods: We determined the effect of quenchers (proteins or lipids) on the fluorescence signal of two
fluorescence-based cell-free assays: the rhodamine 123 (RHD)-based assay, and a previously described assay based
on dichlorodihydrofluorescein (DCF) in patients with systemic inflammation or atherosclerosis versus healthy
subjects.
Results: We found lipid-probe interactions between the non-fluorescent substrate and the lipid, which affect the
observed rate of change of fluorescence after addition of lipids to DHR and DCFH. These interactions depended on:
sample collection and storage, types and concentrations of lipid and fluorescent probe, method of HDL isolation,
diluents and matrices, and pH. The RHD-based assay yielded reproducible measurements despite fluorescence
quenching, while the DCF-based assay displayed more experimental variability. Furthermore, the lipid-probe
interactions varied according to the setting of systemic inflammation when using apolipoprotein (apo) B-depleted
plasma. However, under fixed conditions the rhodamine assay could reliably detect similar mean relative differences
in the redox activity of HDL samples between different groups of patients using either purified HDL or apo-B
depleted plasma.
Conclusions: Lipid-probe interactions should be considered when interpreting the results of fluorescence assays for
measuring lipid oxidative state. Ideally, samples should be freshly obtained and purified HDL should be utilized
rather than Apo B-depleted serum. Assay variability can be reduced by strict standardization of conditions
(particularly sample collection, storage, lipid isolation method). Data comparisons between different studies similarly
require strict standardization of conditions between studies and this caveat must be considered when using these
assays to study the role of HDL function in the development of atherosclerosis in vivo.* Correspondence: tkelesidis@mednet.ucla.edu
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There is a continuing search for new biomarkers of
increased risk for atherosclerotic disease. High-density
lipoproteins (HDL) function rather than absolute level
may be a more accurate indicator for risk of developing
atherosclerosis [1]. Measuring HDL cholesterol levels
provides information about the size of the HDL pool,
but does not predict HDL composition or function.
Robust assays to evaluate the function of HDL are
needed to supplement the measurement of HDL chol-
esterol levels in the clinic [2]. Currently, HDL func-
tional properties are most often determined by cell-
based assays [3-7]. However, the limitations of these
cell-based assays render them impractical to scale up
for large-scale clinical trials.
We previously developed a cell-free assay that measures
HDL function by testing the effect of HDL on the produc-
tion of reactive oxygen species (ROS) after oxidation and
conversion of dichlorodihydrofluorescein diacetate (DCF-
DA) to fluorescent DCF (2',7'-dichlorofluorescein) [3]. Al-
though this assay yielded results that correlated to the
cell-based assay, it has not found widespread usage due to
technical difficulties in getting consistent results across
other researchers. Thus, we recently developed an alterna-
tive cell-free biochemical assay to quantify the redox acti-
vity of HDL [8].
The new assay measures the products of redox cyc-
ling as the rate of oxidation of the fluorogenic probe
dihydrorhodamine-123 (DHR) to fluorescent rhoda-
mine 123 (RHD) [8,9]. Thus, the redox activity of
HDL is assessed in terms of capacity to engage in
redox cycling (1;8). This assay provides a readout that
is highly correlated to a validated cell-based assay
when using purified HDL [6,7,10], yet is reproducible,
and amenable to high-throughput implementation.
A key factor in interpreting both cell-free assays of
HDL is potential lipid-probe interactions affecting the
fluorescent readout. We have observed that such
interactions can affect the fluorescent signal inde-
pendently of the redox effects of HDL, and thus
could be confounders [8]. Thus, the aims of this
study are to investigate lipid-probe interactions by
testing lipids with different oxidative properties in
the two different fluorescence-based cell free assays
and to determine various factors that affect these
lipid-probe interactions. We determined these effects
using blood samples from subjects with atheroscler-
osis such as coronary artery disease (CAD) and from
patients with systemic inflammation such as Human
Immunodeficiency virus (HIV-1)-infected individuals.
Understanding these biochemical interactions in fluor-
escent cell-free assays is important for using these
assays as tools to measure functional properties of
HDL.Materials and methods
Subjects
Ten blood samples were randomly selected from pre-
treatment samples remaining from a previously
described study in which all patients had coronary artery
disease or equivalent defined by the National Cholesterol
Education Program Adult Treatment Panel III criteria
[11] as previously described [8]. 50 Human Immunodefi-
ciency virus (HIV-1)-infected individuals on combin-
ation antiretroviral therapy with suppressed viremia
(below 50 copies of RNA/ml) (48 males and 2 females;
median age 44, range 18–53 years) were recruited at the
University of California, Los Angeles (UCLA) as previ-
ously described [8]. Sixty normal volunteers (52 males
and 8 females; median age 42, range 18–57 years) were
recruited under a protocol approved by the Human Re-
search Subject Protection Committee of the University
of California, Los Angeles. Fifty of them were matched
by age and sex to the 50 HIV-1 infected individuals.
Reagents
Dihydrorhodamine 123 (DHR) and Dihydrodichloro-
fluorescein diacetate (DCFH-DA) were obtained from
Molecular Probes (Eugene, OR). DHR was prepared as a
stock of 50 mM in dimethyl sulfoxide (DMSO) and
DCFH was prepared as previously described [8,12]. Iron-
free HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid)-buffered saline (HBS, HEPES 20 mM,
NaCl 150 mM, pH 7.4) was prepared as previously
described [8,9]. The DHR stock was diluted 1:1000 in
HEPES saline solution to prepare a working solution of
50 μM. Purified Apolipoprotein A-I from human plasma
was obtained from Sigma-Aldrich (St. Louis, MO). Oxi-
dized l-α-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phos-
phorylcholine (oxPAPC) was prepared as previously
described [3].
HDL and LDL purification
HDL and Low-Density Lipoprotein (LDL) were isolated
from cryopreserved human plasma by ultracentrifuga-
tion, Polyethylene glycol (PEG) precipitation and fast
performance liquid chromatography (FPLC), aliquoted
and stored as previously described [13-17]. HDL and
LDL cholesterol were quantified using a standard colori-
metric assay (Thermo DMA Co., San Jose, CA, USA) as
previously described [3].
DCF-based cell-free assay of HDL function
The DCF-based cell-free assay was performed as previ-
ously described (3;12). Kinetic determination of fluores-
cence was performed by measuring the rate (slope) of
oxidation of DCFH over 50 minutes after addition of a
specific amount of lipid (HDL, LDL) as previously
described [8]. Endpoint determination of fluorescence at
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(HDL, LDL and oxPAPC) was performed as previously
described (3;8;12).
RHD-based cell-free assay of HDL function
Quadruplicates of HDL (2.5 μg of cholesterol unless
otherwise specified) were added to 96-well plates (poly-
propylene, flat bottom, black, Fisher Scientific, USA).
HBS was added to each well to a final volume of 150 μl,
followed by addition of 25 μl of the 50 μM DHR working
solution, for a total volume of 175 μl (final DHR concen-
tration of 7 μM). Immediately following DHR addition,
the plate was protected from light and placed in the
fluorescence plate reader (at 37 °C). The fluorescence of
each well was assessed at two minute intervals over an
hour with a Synergy 2 Multi-Mode Microplate Reader
(Biotek, Vermont, USA), using a 485/538 nm excitation/
emission filter pair with the photomultiplier sensitivity
set at medium. Determination of oxidation rate of DHR
was performed by measuring the slope of fluorescence
increase over 50 minutes after addition of a specific
amount of lipid (HDL, LDL) as previously described [8].
Endpoint determination of fluorescence at 0 and 50 min-
utes after addition of a specific amount of lipid (HDL,
LDL and oxPAPC) was performed as previously


















































Figure 1 Dose-dependent decrease in DHR oxidation rate (as measur
incubation with increasing concentration of HDL (triangles) and LDL
oxPAPC (circles) that was prepared as described in Materials and Met
each sample was normalized to the slope of oxidation of DHR and the % r
correlation between the relative % slope and the added amount of lipids i
from 3 independent experiments.as the mean of quadruplicates for the wells containing the
HDL sample.
Statistical analysis
Statistical analysis was performed using Excel (Microsoft
Corporation, Seattle, WA) and STATA statistical soft-
ware (version 12). Continuous variables were explored
for normal distribution and normally distributed con-
tinuous variables were expressed as mean ± standard de-
viation and non-normally distributed continuous
variables were expressed as median and interquartile
range (IQR). The comparison of quantitative variables
among 2 groups was done using the Student-t test for
normally distributed variables and the Mann–Whitney
U test for non-normally distributed variables. Correla-
tions between different variables were calculated using
the Pearson correlation coefficient or the non-
parametric equivalent. Significance was set at p< 0.05 (2
tailed).
Results
Lipid-probe interactions affect the observed rate of
fluorescence after addition of lipids to DHR
In our previously reported assay that measures the
redox activity of HDL, we unexpectedly observed a
significant reduction in fluorescence signal after initial7 9 11 13 15







ed by changes in fluorescence per minute over 50 minutes) by
(squares) that were isolated by FPLC from a healthy donor,
hods and stable amount of DHR (50 uM). The slope of oxidation of
elative oxidation slope and quenching is shown on the y axis. The
s shown. The values represent means ± SD of quadruplicate samples
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decrease, we compared the effect of addition of different
lipids with known oxidative properties on the oxidation
rate of DHR (Figure 1). LDL and L-α-1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC),
both lipids known not to be anti-oxidant, lead to sig-
nificant decrease in the rate of observed fluorescence
after addition to DHR (Figure 1). Because these lip-
ids are pro-oxidant, this suggested that lipid-probe
interactions cause interference with the fluorescence
readout.
DHR and DCFH differ in their lipid-probe interactions
The same lipids were tested for their effects in the previ-
ously described Dihydrodichlorofluorescein diacetate
(DCF) assay of HDL (3;12). HDL, LDL, and oxPAPC all
lead to reduction in the DCF fluorescence and the fluor-
escence rate of DCFH-DA (Figure 2), but only at higher
lipid concentrations (> 7.5 μg). However at lower lipid
concentrations (< 5 ug) no reduction in the observed
fluorescence was observed, in contrast to DHR (Figure 1).
In addition the % fluorescence quenching (defined as re-
duction in the fluorescence signal of the fluorochrome














































Figure 2 Dose-dependent decrease in DCF oxidation rate (as measure
incubation with increasing concentration of HDL (triangles) and LDL
oxPAPC (circles) that was prepared as described in Materials and Met
oxidation of each sample was normalized to the slope of oxidation of DCF
axis. The correlation between the relative % slope and the added amount
samples from 3 independent experiments.observed with DCF at higher lipid concentrations (>7.5
ug) was less prominent compared to the % fluorescence
quenching that was observed with DHR (Figure 1).
Thus, the lipid-probe interactions in fluorescence-based
cell free assays that determine oxidative properties of
lipids depend on both the type of the fluorochrome used
in the assay and the concentration of the lipid, and are
more prominent with DHR compared to DCFH.Lipid-probe interactions depend on the concentration of
the lipid
To determine whether the lipid-DHR interactions were
dependent on the concentration of the lipid, increasing
concentrations of cholesterol (HDL, LDL) and oxPAPC
were incubated with 50 μM of DHR. The correlation
observed between the quantity of the lipid added and
DHR fluorescence and the oxidation rate of DHR (DOR)
(Figure 1) was inverse and highly significant. Similarly,
the lipid-DCF interactions were also dependent on the
concentration of the lipid, and increasing concentrations
of cholesterol (HDL, LDL) and oxPAPC lead to reduc-
tion in the DCF fluorescence and oxidation rate of
DCFH (Figure 2).7 9 11 13 15







d by changes in fluorescence per minute over 50 minutes) by
(squares) that were isolated by FPLC from a healthy donor,
hods and stable amount of DCFH (200 ug/ml). The slope of
and the % relative oxidation slope and quenching is shown on the y
of lipids is shown. The values represent means ± SD of quadruplicate
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the fluorescent probe
We previously showed that increasing concentrations of
DHR (1–50 μM) resulted in increasing oxidation rate of
both LDL and HDL, and that the oxidation rate of LDL
was higher than that of HDL [8]. To further investigate
the concentration dependent interaction between fluor-
escent probes and lipids, increasing doses of probes were
added to specific amount of HDL or LDL (2.5 μg). To
increase the sensitivity of the assay to detect smaller dif-
ferences in oxidative properties of lipoproteins, we used
50 μM of DHR for all our experiments, which is a con-
centration that has been previously used to quantify
redox activity [9]. Similarly, increasing concentrations of
DCFH resulted in increasing oxidation rate of both LDL
and HDL (Figure 3). Again no significant quenching was
observed with DCF and lower amounts of lipids (2.5 ug)
(Figure 2).
Lipid-probe interactions occur between the
non-fluorescent substrate and the lipid rather than the
oxidized fluorescent product and the lipid
We then determined the nature of the lipid-probe inter-
actions and whether the lipid interacts with the non-
fluorescent substrate, the oxidized fluorescent product
or both. When most of DHR was converted (oxidized)
into rhodamine (RHD) the lipid-probe interactions were
significantly less prominent, suggesting that fluorescence
quenching is the result of DHR-HDL interaction rather
than RHD-HDL interaction [8]. Similarly, when most of
DCFH was converted (oxidized) into DCF, the lipid-
probe interactions again were significantly less promin-
ent, suggesting that fluorescence quenching is the result

























Figure 3 Dose-dependent increase in DCFH oxidation rate (as measur
specific amount (2.5 ug) of HDL (light gray columns), or LDL (solid bl
healthy donor with increasing concentration of DHR (1, 10, 20, 30, 40
incubation at 37° C. The values represent means ± SD of quadruplicate saminteraction (Figure 4). Thus, the lipid-probe interactions
in fluorescence-based cell free assays that determine oxi-
dative properties of lipids occur mostly between the
non-fluorescent substrate and the lipid.Different methods of HDL isolation affect lipid-probe
interactions
Different methods of HDL purification may affect lipid-
probe interactions and the readout of the RHD-based
assay. The observed oxidation rate of DHR (DOR) was
significantly higher when the HDL had been isolated by
ultracentrifugation compared to HDL isolated by other
methods such as fast performance liquid chromatog-
raphy (FPLC) [8]. Similarly, the oxidation rate of DCFH
was significantly higher when HDL isolated by ultracen-
trifugation was added compared to when the same
amount of HDL isolated by FPLC was added (Figure 5).The concentration dependent effect of addition of HDL
on oxidation of the fluorogenic probe is not secondary to
lipid-free apolipoprotein AI (apoAI)
It has previously been shown that lipid-free apoAI has
no concentration dependent effect on oxidation of DHR
at concentrations that correspond to the physiologic
range of concentration of apoAI in normal subjects (90–
130 mg/dl) [3,8,18], Similarly, the addition of increasing
concentrations of lipid-free apoAI (2.5-10 mg/dl) did not
have a concentration dependent effect on oxidation of
DCFH (Figure 6) confirming our previous results [3].
The protein (lipid free apoAI) -probe interactions were
more prominent with DHR compared to DCFH [8]
(Figure 6).50 100 200
of DCFH added (ug/ml)  
CFH LDL
ed by changes in fluorescence per minute) after incubation of
ack columns) that were isolated by ultracentrifugation from a
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Figure 4 Oxidation of DCFH in the presence of six different samples of HDL [3 from patients with coronary artery disease (CAD) and 3
from healthy volunteers (Non CAD)] was assessed as described in Methods, using 2.5 μg (cholesterol) of added HDL. The slope of
oxidation of each sample was normalized to the slope of oxidation of DCFH and the % relative oxidation slope and quenching is shown on the y
axis. The data (means of quadruplicates) from three independent experiments are plotted. The experiments were repeated after DCFH (grey
columns) was almost fully oxidized (air oxidation at room temperature for 5 hours). There was a ~40-fold increase in the slope of oxidation of
DCFH after 5 hours of air oxidation. The oxidized DCF (DCF ox) was diluted 40-fold to give comparable fluorescence to the baseline DCFH and
experiments after addition of HDL were repeated. Addition of HDL did not cause significant fluorescence quenching and there was a significant
increase in the variability of oxidation of DCFH compared to baseline DCFH. These results indicate that most of DCFH had converted into DCF
and did not react with HDL confirming the fact that fluorescence quenching is the result of DCFH-HDL interaction.
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Different methods of HDL purification and storage
utilize varying compositions of diluent [8]. Moreover,
different types of diluents utilized for HDL suspension
and storage in preparation for HDL functional assays
can affect the readout of the RHD-based assay [8]. Spe-
cifically, use of sodium azide and/or standard
phosphate-buffered saline (PBS) significantly increased
fluorescence quenching and reduced oxidation of DHR
compared to the buffered saline diluent (HBS) [8]. The
effects of different diluents on lipid-probe interactions
were confirmed in the DCF-based assay; addition of
phosphate (PBS) and/or sodium azide significantly
enhanced fluorescence quenching and increased experi-
mental variability compared to use of HBS (data not
shown). Of note, in the previous DCF-based assay the
diluent that was used was PBS with sodium azide and
this may also partially explain the increased experimen-
tal variability observed with that method (3;12). These
results suggest that use of saline without sodium azide
and PBS reduces lipid-probe interactions and improves
the sensitivity of the assay to detect differences in oxida-
tive properties of lipids between different samples.Changes in pH can affect lipid-probe interactions
It has previously been demonstrated that oxidation of
DHR was also pH-dependent and that the oxidation rate
of DHR was highest at pH 3, least at pH 9, and similar
for pH 5 and 7 [8]. However in the DCF-based assay the
oxidation rate of DCFH was highest at pH 9, least at pH
3, and similar for pH 5 and 7 (data not shown). These
results suggested that the lipid-probe interactions are
less prone to pH effects near the physiologic range and
careful titration of the pH of the HBS diluent may re-
duce experimental variability.Matrix effects can affect lipid-probe interactions
We determined the effects of different matrices (plasma
with citrate versus plasma with heparin versus serum)
on the rate of oxidation of DHR (DOR). We found that
the HDL samples isolated from plasma with heparin and
sera had significantly (p< 0.05) higher DOR values com-
pared to the same HDL samples isolated from plasma
citrate (Figure 7) but the DOR values correlated signifi-
cantly (R² = 0.51, p< 0.01; R² = 0.43, p< 0.01 respect-
ively) (Figure 8).
Figure 5 Influence of method of HDL isolation on HDL-DCFH
interactions. DCFH was exposed to 2.5 μg (cholesterol) of
FPLC-purified (FPLC) or ultracentrifugation-purified HDL (UC)
that was isolated from 10 patients with coronary artery disease
(CAD) and 10 healthy volunteers (Non CAD) as described in
Materials and Methods. Each sample was run in quadruplicate. The
median slopes of oxidation are expressed as % oxidation slopes
compared to the median slope of oxidation of DCFH. The median
oxidation rate of DCFH was significantly higher when HDL isolated
by ultracentrifugation was added compared to when HDL isolated
by FPLC was added (p< 0.05, n = 20). * p< 0.05.
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may partially explain the increased experimental
variability observed with the DCF-based assay compared
to the RHD-based assay
We observed a significantly higher experimental variabil-
ity (as assessed by larger error bars) in the DCF-based
assay compared to the RHD-based assay (Figures 1, 2, 3,
4, 5, 6, 7, 8) [8]. Figure 9 summarizes the factors that
can affect lipid-probe interactions and that can partially
explain this increased experimental variability of the
DCF-based assay compared to the RHD-based assay.
The clinical status of study subjects can affect the degree
of lipid-probe interaction when apolipoprotein (apo)
B-depleted plasma is assayed in the RHD-based assay
Although the RHD assay may allow high throughput
study of HDL in the setting of large scale studies [8], the
limiting factor is HDL isolation, prompting consider-
ation of convenient approaches such as PEG precipita-
tion [19]. We determined (apo) B-depleted plasma-DHR
interactions for HIV-1-infected subjects (systemically
inflamed) versus healthy subjects, using HDL that had
been isolated by ultracentrifugation versus PEG precipi-
tation (Figure 10). The oxidation rate of DHR (DOR)
was significantly higher (p< 0.05) in the group with
HIV-1 infection compared to healthy subjects when
ultracentrifuged HDL was assayed (Figure 10), but lower
when (apo) B-depleted cryopreserved plasma was used(Figure 11). Within groups, the relationships of DOR
measurements using PEG-precipitated versus ultracen-
trifuge purified HDL were consistent, but these relation-
ships differed between groups (Figure 12). This
suggested that other plasma factors provoked by inflam-
mation and or cryopreservation that remained in the
apo-B depleted plasma but not in ultracentrifuged HDL
interfere with the fluorescence readout [20].
Discussion
Recent interest has focused on the functional conse-
quences of HDL oxidation [1,21]. Oxidation conceivably
could contribute to the formation of dysfunctional HDL,
proposed to be involved in human cardiovascular disease
[22-24]. Levels of reactive oxygen species (ROS) such as
lipid hydroperoxides that are produced from oxidation
of lipoproteins are significantly associated with func-
tional properties of HDL [3]. To study these issues,
fluorescence-based reporter assays have been applied to
probe protein-protein interactions and monitor levels of
ROS [25-29]. The generation of ROS can be followed as
an increase in fluorescence that can be detected by dif-
ferent fluorochromes such as DCF [3] and rhodamine
123 (RHD) [9]. In the DCF-based cell-free assay the
function of HDL is determined based on the capacity of
HDL to prevent the formation or to inactivate oxidized
phospholipids produced by LDL [3]. However, technical
difficulties with this assay have limited its utility. Thus,
we recently developed a novel cell free assay that is
based on the oxidation rate of the fluorochrome dihy-
drorhodamine 123 (DHR) as a surrogate marker of the
functional properties of HDL, which is more robust
compared to the previous DCF-based assay [8].
Fluorescence, however, is an environmentally sensitive
phenomenon [25,30]. Environmental factors may de-
excite the fluorophore, and/or quench fluorescence
[25,30]. Quenching of fluorescence is defined as loss of
fluorescence signal due to short-range interactions be-
tween the fluorophore and the local molecular environ-
ment [25,30]. Fluorophores exhibit changes in
fluorescence due to environmental factors such as pH,
solvent, presence of quenchers (such as proteins or
lipids) that can cause concentration dependent decreases
in fluorescence readout [25,30]. The effect of apolipo-
proteins and lipids on fluorescent probes (lipid-probe
interactions) has minimally been studied [31]. Under-
standing the lipid-probe interactions in the setting of
cell-free biochemical assays that are based on fluores-
cence to determine functional properties of HDL (such
as the DCF-based and RHD-based assays) is important
for interpretation of the results of these functional assays.
Herein, we identify factors that are important for lipid-
probe interactions and that may increase experimental



























































Figure 6 The effect of purified, commercially available, lipid-free apolipoprotein AI (ApoAI) from a healthy donor on DCF oxidation
rate was assessed by incubation of 200 ug/ml of DCFH with increasing concentration of ApoAI (0.5 -10.0 mg/dl). The slope of oxidation
of each sample was normalized to the slope of oxidation of DCF and the % relative oxidation slope and quenching is shown on the y axis as
described in Figure 5A. The values represent means ± SD of quadruplicate samples. There was no concentration dependent effect of apoAI (at
concentration> 2 mg/dl) on DCFH oxidation rate.
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the lipoprotein (type and concentration of lipoprotein,
presence of apolipoproteins, purification method of lipo-

































Figure 7 HDL was isolated from plasma (with heparin or citrate as an
ultracentrifugation. Oxidation of DHR in the presence of these 12 differen
(cholesterol) of added HDL. The slope of oxidation of each sample was nor
slope and quenching is shown on the y axis. The data (means of quadrupl
the HDL samples isolated from plasma with heparin and from sera had sig
respectively) compared to the same HDL samples isolated from plasma citrand concentration of probe) and environmental factors
(type and concentration of diluent, temperature, pH,
matrix effects) all can affect the fluorescence signal and
lipid-probe interactions (Figure 9).eparin plasma Serum
**
ticoagulants) and serum of 12 different healthy volunteers, using
t HDL samples was assessed as described in Methods, using 2.5 μg
malized to the slope of oxidation of DHR and the % relative oxidation
icates) from three independent experiments are plotted. We found that




































































Figure 8 HDL was isolated from plasma (with heparin or citrate
as anticoagulants) and serum of 12 different healthy
volunteers, using ultracentrifugation. Oxidation of DHR in the
presence of these 12 different HDL samples was assessed as
described in Methods, using 2.5 μg (cholesterol) of added HDL. The
slope of oxidation of each sample was normalized to the slope of
oxidation of DHR and the % relative oxidation slope and quenching
is shown on the y and x axes. The data (means of quadruplicates)
from three independent experiments are plotted. We found that the
DOR values from the HDL samples isolated from plasma with
heparin correlated significantly (p< 0.05) with those from the HDL
samples isolated from sera (R2 = 0.41, p = 0.03) or plasma citrate
(R2 = 0.51, p< 0.01). The DOR values from the HDL samples isolated
from plasma with citrate correlated significantly (p< 0.05) with those
from the HDL samples isolated from sera (R2 = 0.43, p< 0.01).
Kelesidis et al. Lipids in Health and Disease 2012, 11:87 Page 9 of 13
http://www.lipidworld.com/content/11/1/87Firstly, factors related to the lipoprotein such as the
type and concentration of lipoprotein, lipid-lipid interac-
tions presence of apolipoproteins, method of isolation of
lipoprotein, play a major role in lipid-probe interactions.
In the previous DCF-based assay we demonstrated lipid-
probe interactions between the fluorochrome DCFH with
various lipids such as HDL, LDL, oxidized l-α-1-palmitoyl-
2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC),
1-palmitoyl-2-oxovaleryl-sn-glycero-3-phosphorylcholine
(POVPC), hydroperoxyoctadecadienoic acid (HPODE)
[3]. Here we confirm the lipid-probe interactions between
DCFH and LDL and oxPAPC and demonstrate that in-
creasing concentrations of these lipids lead to changes
in the fluorescence signal, and increasing concentrations
of HDL lead to a decrease in the fluorescence signal
(HDL-DCFH interactions), consistent with our previous
results [3].
We subsequently studied the interactions of lipids with
DHR. We found that addition of lipids, including pro-
oxidant lipids contained in lipoproteins, lead to signifi-
cant decrease in oxidation signal of DHR. It has been
demonstrated that the interaction of DHR-HDL is re-
sponsible for the fluorescence quenching in the RHD-
based assay [8]. Similarly to the HDL-DCFH interactions
increasing concentrations of HDL lead to a decrease in
the fluorescence signal of RHD. However, the RHD-
based assay of HDL redox activity yields highly reprodu-
cible measurements despite fluorescence quenching [8].
In addition, the inverse correlation between HDL con-
centration and oxidation rate of DHR allows quantifica-
tion of functional properties of HDL using very low
concentrations of HDL (≤2.5 ug per sample). Thus,
using this assay we were able to quantify relative differ-
ences in the redox activity of different HDL samples that
correlate with their functional properties [8].
We also found that addition of two lipids can lead to
increased experimental variability in determination of
the fluorescence signal compared to the highly consist-
ent results seen with HDL alone [8]. Co-incubation of
stable amount of DHR (50 uM) with different concentra-
tions of two lipids simultaneously (HDL with LDL, HDL
with oxPAPC) so that the total amount of lipid was fixed
at 5 μg increased the variability of the assay (as deter-
mined by the standard errors in quantification of the
fluorescence signal) compared to when the same amount
(5 μg) of each lipid was incubated with DHR independ-
ently [8]. Similar results were observed with the DCF-
based assay (data not shown). Thus, based on these re-
sults, we avoided co-incubation of two lipids in the novel
RHD-based assay that was based on the interactions of
only one lipid (HDL) with a fluorescent probe [8].
The lipid-probe interactions are mostly caused by
interaction of the non-fluorescent probe (e.g. DHR) with
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Figure 9 Summary of factors that affect lipid-probe interactions. The RHD-based assay has reduced experimental variability compared to the
DCF-based assay. This can be partially explained by the following differences between the RHD-based assay and the DCF-based assay a) Use of a
single lipid (HDL) in the RHD-based assay versus 2 lipids (HDL and LDL) in the DCF-based assay b) DHR is relatively stable, and oxidizes at a
predictable rate when exposed to air compared to DCFH which is more unstable and prone to auto-oxidation c) Formation of DCFH from
DCFH-DA can be mediated by esterases that are carried over variably during the lipid purification process, while DHR requires no activation and
is not prone to this effect d) Use of HBS buffer rather than PBS/azide e) Lipid-DHR interactions are less affected by changes in pH compared to
DCFH-lipid interactions.
Figure 10 HDL was isolated from plasma of 50 patients with
HIV infection and 50 healthy subjects, using ultracentrifugation
and PEG precipitation as described in Methods. Oxidation of
DHR in the presence of these 100 different HDL samples was
assessed as described in Methods, using 2.5 μg (cholesterol) of
added HDL. The slope of oxidation of each sample was normalized
as ratio to the DOR of a control pool of HDL isolated from plasma of
50 healthy control subjects using ultracentrifugation and PEG
precipitation as described in Methods. The normalized DOR (nDOR)
is shown on the y axis. The data (means of quadruplicates) from
three independent experiments are plotted. The median nDOR value
from HIV-infected subjects was significantly (p< 0.001) higher
(1.31; IQR: 1.18, 1.45) compared to the median nDOR value from
healthy subjects (0.87; IQR: 0.79, 0.95) when HDL was purified using
ultracentrifugation. This study had≥ 85% study power to detect a
50% difference of nDOR (as a measure of HDL function) between
patients with systemic inflammation (such as HIV infected subjects)
and healthy subjects using non-parametric tests for independent
samples at alpha 0.05 (two-sided).
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http://www.lipidworld.com/content/11/1/87probe (e.g. DHR) has been mostly converted into fluor-
escent probe (e.g. RHD), the lipid probe interactions are
minimal. Moreover, addition of detergent (SDS) in the
DHR+HDL reaction causes an increase in fluorescence
(data not shown), consistent with a reduction in quench-
ing due to dissociation of lipid-dye complexes [8]. It has
also been shown that the reduction in the fluorescence
signal of RHD after addition of HDL occurs immedi-
ately, when minimal oxidation of DHR has occurred and
minimal amount of RHD is present [8]. This indicates
that the immediate reduction in fluorescence afterFigure 11 Contrary to when HDL was purified using
ultracentrifugation (Figure 10), the normalized median
oxidation rate of DHR (nDOR) was significantly (p< 0.05) lower
in patients with HIV (0.74; IQR: 0.65, 0.84) compared to healthy



































Figure 12 HDL was isolated from plasma of 50 patients with
HIV and 50 healthy subjects, using ultracentrifugation and PEG
precipitation and DOR values were determined as described in
Figure 10. We found that the nDOR values from the HDL samples
isolated using ultracentrifugation (UC) correlated significantly
(p< 0.05) with those from the (apo) B-depleted plasma using PEG
precipitation in both healthy subjects (A) (R2 = 0.65, p< 0.001) and
HIV infected (B) (R2 = 0.47, p< 0.01).
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tions (DHR-lipid interactions). Finally, using LC/MS/MS
analysis it has been shown that differences in fluores-
cence after addition of same amount of different HDL
samples correspond to real differences in the degree of
oxidation of DHR [8].
Different methods of HDL purification such as ultra-
centrifugation, fast performance liquid chromatography
(FPLC), use of dextran sulfate and precipitation withpolyethylene glycol (PEG) may affect lipid-probe interac-
tions [8]. The oxidation rates of DHR and DCFH are sig-
nificantly higher for HDL isolated by ultracentrifugation
versus other methods [8]. However, the lengthy process
of ultracentrifugation may yield additional ROS, contrib-
uting to this observation [32]. Removal of serum albu-
min bound to HDL by ultracentrifugation may also alter
the association of nonpolar and polar substances includ-
ing ROS associated with lipoproteins [32,42]. Thus, al-
though results using different methods of HDL isolation
may correlate significantly [8], ideally a consistent meth-
od of HDL isolation for all the samples in one study
should be used when measuring relative differences in
the oxidative properties of HDL between these different
samples.
We determined the effect of lipid-free apolipoprotein
A-I, the major apolipoprotein of HDL, on the fluores-
cent probes. It has previously been shown that, in con-
trast to apoJ, coincubation of apoA-I with PAPC plus
HPODE did not prevent the oxidation of PAPC by
HPODE and did not prevent the increase in DCF fluor-
escence [3]. Consistent with these results we demon-
strated that addition of lipid-free apoAI did not cause a
concentration dependent effect on oxidation of both
DHR and DCFH at concentrations that correspond to
the physiologic range of concentration of apoAI in nor-
mal subjects (90–130 mg/dl) (1;18). Thus, the fluores-
cent probes used in biochemical assays of HDL function
quantify relative differences in the redox activity of HDL
that cannot be attributed to apolipoprotein A-I.
Moreover, factors related to the fluorescent probe such
as the type and concentration of probe play a major role
in lipid-probe interactions. Indeed, the lipid-probe inter-
actions in the DCF-based and the RHD-based assays are
distinct. Differences in the chemical structure and/or
charge between DHR and DCFH can explain these dif-
ferences since DHR is positively charged while DCFH is
negatively charged [33-41]. In contrast to DCFH, DHR
has less complicated matrix effects than DCFH, is less
prone to auto-oxidation, is unaffected by esterases that
may influence the fluorescence signal independently of
oxidation, and does not form a nonfluorescent lactone
when the oxidation product is exposed to a pure lipid
environment [33-41].
Environmental factors (type and concentration of dilu-
ent, temperature, pH) can also affect the fluorescence
signal and lipid-probe interactions. Changes in fluores-
cence that were observed with different buffers are likely
due to an effect of the buffer on the HDL complex and
hence the interaction between the buffer and the fluor-
escent indicator. In the previous DCF-based assay the
buffer was phosphate buffered saline (PBS) containing
sodium azide (pH 7.4), whereas the RHD assay utilized
HEPES-saline buffer (pH 7.4) to quantify redox activity
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http://www.lipidworld.com/content/11/1/87of DHR [9]. Azide and PBS reduced the oxidation rate of
DHR and increased its variability, and increased the
quenching effect of lipids. Thus, we conclude that PBS
and azide should be avoided in cell-free fluorogenic
methods.
We also examined the effect of pH on the interaction
between lipids and oxidation of fluorescent probes. The
effect of pH on the lipid-probe interactions was different
in the DCF-based compared to the RHD-based assay but
in both assays there was reduced variability in oxidation
rate of the fluorescent probes at pH of 7.4 compared to
extremes of pH, suggesting that this is the optimal pH
for these assays.
We also determined the effects of different matrices
(plasma versus serum) on the fluorescence readout and
DOR. We found that the HDL samples isolated from
heparinized plasma or serum had significantly higher
DOR values compared to the same HDL samples iso-
lated from plasma citrate, although the DOR values cor-
related significantly between different matrices. Such
differences between serum and plasma measurements
could be, at least in part, related to products from the
clotting cascade found in serum that may affect oxida-
tion reactions. Our observation that heparin may inter-
fere with determination of ROS using fluorescent probes
are consistent with previous studies [32], suggesting that
plasma from citrate-treated blood or serum may be pre-
ferable for the RHD assay.
Polyethylene glycol (PEG) precipitation is a conveni-
ent, reproducible, and rapid method to extract HDL
from patient serum [19], which would be ideal for high
throughput fluorogenic HDL assays. However, while PEG
precipitation removes apo B-containing particles [19],
apo-B depleted plasma contains a significant amount of
HDL-associated proteome that can be altered during in-
flammatory conditions [20] and cryopreservation and can
cause protein-probe interactions in fluorescence-based
biochemical assays that measure redox activity of HDL.
The interactions of apo-B depleted serum and DCFH
were not prominent in the previous DCF assay [3]. Con-
sistent with our results that protein-DCFH interactions
are less prominent compared to DHR-protein interac-
tions, Patel et al. demonstrated that a significant reduction
in the fluorescent signal of DCF is present only at higher
concentrations of apo-B depleted serum [19]. However,
contrary to when HDL was purified using ultracentrifu-
gation, the DOR was significantly lower in patients with
HIV infection compared to healthy subjects when (apo)
B-depleted plasma from cryopreserved samples was used.
Alterations of the proteome present in the apo-B depleted
plasma (but not in purified HDL) that is associated with
HDL and which is upregulated during inflammatory con-
ditions [20] and cryopreservation may enhance protein-
probe interactions and may explain these results.In conclusion, fluorescence based cell-free assays offer
an attractive alternative to current cell-based assays for
measuring functional properties of HDL, and may be
more precise because they measure an important bio-
chemical process underlying the biological phenotype. We
demonstrate that the reduction in the oxidation signal
that is observed after addition of HDL to fluorochrome
such as RHD and DCF is secondary to fluorescence
quenching and lipid-probe interactions. Thus controlling
for lipid-probe interactions that are observed in these
assays is important for interpretation of the results of
these assays and comparisons of results within and be-
tween studies.Abbreviations
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